RecruitingPhase 3NCT03588975

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Studying Osteochondritis dissecans

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Vericel Corporation
Principal Investigator: Jonathan Hopper
Vericel Corporation
Intervention: MACI(biological)
Enrollment: 45 enrolled
Eligibility: 10-17 years · All sexes
Timeline: 2018 – 2027

Study locations (12)

Stanford University, Palo Alto, California, United States
Shriner's Hospital for Children Northern California, Sacramento, California, United States
University of California Davis Health, Sacramento, California, United States
Ochsner Sports Medicine Institute, New Orleans, Louisiana, United States
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
Akron Children's Hospital, Akron, Ohio, United States
The Ohio State University Jameson Crane Sports Medicine Institute, Columbus, Ohio, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Penn Sports Medicine Center, Philadelphia, Pennsylvania, United States
Texas Children's Hospital, Houston, Texas, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03588975 on ClinicalTrials.gov

Other trials for Osteochondritis dissecans

Additional recruiting or active studies for the same condition.

See all trials for Osteochondritis dissecans →

← Back to all trials